Closing Bell Overtime: Are Investors Too Rosy On China? And Why Pfizers New Weight Loss Drug Could Unseat Ozempic 5/22/23
The Nasdaq closed higher while the Dow fell in today\u2019s session. Wells Fargo\u2019s Darrell Cronk and Baird\u2019s Ross Mayfield break down the market action. Is China\u2019s economic reality less rosier than the investment banks are forecasting? Rockefeller International\u2019s Ruchir Sharma makes the case for why investor should be wary of the strong bounceback story. A new study shows a Pfizer oral weight loss drug is as effective or even quicker than Ozempic\u2019s injection; BMO analyst Even Seigerman on the investment prospects. Apollo Global\u2019s Torsten Slock on the debt ceiling negotiations and the economic impact that\u2019s already occurring. TransUnion CEO Chris Cartwright on why the American consumer remains strong. Plus, Zoom popped initially on strong earnings numbers; Evercore\u2019s Peter Levine discusses the latest quarter. Tiffany is reopening its flagship store and our Robert Frank gives us a tour and what it means for the share price.